Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis
FDA Panel Votes Unanimously in Favor of First CAR-T Cancer Therapy | RAPS
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy
ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel (CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
FDA committee takes on complex gene therapy safety questions with Novartis' Zolgensma providing lessons learned | Fierce Biotech
How to cover Novartis' $475K CAR-T drug Kymriah? A 'new payment model' is the only way, Express Scripts says | Fierce Pharma
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
Gene Therapy Reviews Return To US FDA Advisory Committee Schedule :: Pink Sheet
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
PDF) Global regulatory challenges of CAR T-cell therapies: approval, pricing, and access
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy | SpringerLink
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
PDF) Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 - Cytotherapy
The Process of CAR-T Cell Therapy | Novartis
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
CAR-T Cell Product Development Guidance Covers Previous Recipients, 'Bridging Therapy' :: Pink Sheet
How will Novartis price its groundbreaking CAR-T med? R&D exec offers some clues | Fierce Pharma
Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
